<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1803257095
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PERTENSIO 125 mg Film-Coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BOSENTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        125
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6115.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C02KX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pertensio tablets contain bosentan, which blocks a naturally occurring hormone called<br />endothelin-1 (ET-1), which causes blood vessels to narrow. Pertensio therefore causes blood<br />vessels to expand and belongs to the class of medicines called &ldquo;endothelin receptor<br />antagonists&rdquo;.<br />Pertensio is used to treat:<br /><strong>&bull; Pulmonary arterial hypertension (PAH):</strong> PAH is a disease of severe narrowing of the<br />blood vessels in the lungs resulting in high blood pressure in the blood vessels (the<br />pulmonary arteries) that carry blood from the heart to the lungs. This pressure reduces the<br />amount of oxygen that can get into the blood in the lungs, making physical activity more<br />difficult. Pertensio widens the pulmonary arteries, making it easier for the heart to pump<br />blood through them. This lowers the blood pressure and relieves the symptoms.<br />Pertensio is used to treat patients with class III pulmonary arterial hypertension (PAH) to<br />improve exercise capacity (the ability to carry out physical activity) and symptoms. The &lsquo;class&rsquo;<br />reflects the seriousness of the disease: &lsquo;class III&rsquo; involves marked limitation of physical<br />activity. Some improvements have also been shown in patients with class II PAH. &lsquo;Class II&rsquo;<br />involves slight limitation of physical activity. The PAH for which Pertensio is indicated can be:<br />&bull; Primary (with no identified cause or familial);<br />&bull; Caused by scleroderma (also called systemic sclerosis, a disease where there is abnormal<br />growth of the connective tissue that supports the skin and other organs);<br />&bull; Caused by congenital (inborn) heart defects with shunts (abnormal passageways) causing<br />abnormal flow of blood through the heart and lungs.<br />&bull; Digital ulcers (sores on the fingers and toes) in adult patients with a condition called<br />scleroderma. Pertensio reduces the number of new finger and toe ulcers that appear.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Pertensio:<br />&bull; If you are allergic to bosentan</strong> or any of the other ingredients of this medicine (listed in<br />section 6).<br /><strong>&bull; If you have liver problems</strong> (ask your doctor)<br /><strong>&bull; If you are pregnant, or could get pregnant</strong> because you are not using reliable<br />contraceptive methods. Please read the information under &ldquo;Contraceptives&rdquo; and &ldquo;Other<br />medicines and Pertensio&rdquo;<br /><strong>&bull; If you are taking cyclosporine</strong> (a medicine used after a transplant or to treat psoriasis)<br />If any of these apply to you, tell your doctor.<br /><strong>Warnings and precautions<br />Tests your doctor will do before treatment</strong><br />&bull; A blood test to check your liver function,<br />&bull; A blood test to check for anaemia (low haemoglobin),<br />&bull; A pregnancy test if you are a woman of child-bearing potential.<br />Some patients taking Pertensio have been found to have abnormal liver function tests and<br />anaemia (low haemoglobin).<br /><strong>Tests your doctor will do during treatment</strong><br />During treatment with Pertensio, your doctor will arrange for regular blood tests to check for<br />changes in your liver function and haemoglobin level.<br /><strong>Blood tests for liver function</strong><br />These will be done every month for the duration of treatment with Pertensio. After an increase<br />in dose an additional test will be done after 2 weeks.<br /><strong>Blood tests for anaemia</strong><br />These will be done every month for the first 4 months of treatment, then every 3 months after<br />that, as patients taking Pertensio may get anaemia.<br />If these results are abnormal, your doctor may decide to reduce your dose or stop treatment<br />with<br />Pertensio and to perform further tests to investigate the cause.<br /><strong>Children and adolescents</strong><br />Pertensio is not recommended in paediatric patients with systemic sclerosis and ongoing digital<br />ulcer disease. Please see also section 3. How to take Pertensio.<br /><strong>Other medicines and Pertensio</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other<br />medicines, including medicines obtained without a prescription. It is especially important to<br />tell your doctor if you are taking:<br />&bull; Cyclosporine A (a medicine used after transplants and to treat psoriasis), which must not be<br />used together with Pertensio<br />&bull; Sirolimus or tacrolimus, which are medicines used after transplants, as these are not<br />recommended to be used together with Pertensio<br />&bull; Glibenclamide (a diabetes medicine), rifampicin (a tuberculosis medicine) or fluconazole (a<br />medicine against fungal infections), nevirapine (an HIV medicine) as these medicines are<br />not recommended to be used together with Pertensio<br />&bull; Other medicines for the treatment of HIV infection, which may require special monitoring<br />if used together with Pertensio<br />&bull; Hormonal contraceptives, which are not effective as the sole method of contraception when<br />you take Pertensio.</p><p><strong>Driving and using machines</strong><br />Pertensio has no or negligible influence on the ability to drive and use machines. However,<br />Pertensio can induce hypotension (decrease of your blood pressure) which can make you feel<br />dizzy, affect your vision and affect your ability to drive and use machines. Therefore, if you<br />feel dizzy or that your vision is blurred while taking Pertensio, do not drive or operate any tools<br />or machines.<br /><strong>Women of child-bearing age</strong><br />Do NOT take Pertensio if you are pregnant or planning to become pregnant.<br /><strong>Pregnancy tests</strong><br />Pertensio may harm unborn babies conceived before starting or during treatment. If you are a<br />woman who could become pregnant, your doctor will ask you to take a pregnancy test before<br />you start taking Pertensio, and regularly while you are taking Pertensio.<br /><strong>Contraceptives</strong><br />If it is possible that you could become pregnant, use a reliable form of birth control<br />(contraception) while you are taking Pertensio. Your doctor or gynaecologist will advise you<br />about reliable contraceptive methods while taking Pertensio. Because Pertensio may make<br />hormonal contraception (e.g., oral, injection, implant, or skin patches) ineffective, this method<br />on its own is not reliable.<br />Therefore, if you use hormonal contraceptives you must also use a barrier method (e.g., female<br />condom, diaphragm, contraceptive sponge, or your partner must also use a condom). Monthly<br />pregnancy tests are recommended while you are taking Pertensio and are of child-bearing age.<br />Tell your doctor immediately if you become pregnant while you are taking Pertensio, or plan to<br />become pregnant in the near future.<br /><strong>Breast-feeding</strong><br />Tell your doctor immediately if you are breast-feeding. You are advised to stop breastfeeding<br />if Pertensio is prescribed for you, because it is not known whether this medicine passes<br />into breast milk.<br /><strong>Fertility</strong><br />If you are a man taking Pertensio, it is possible that this medicine may lower your sperm count.<br />It cannot be excluded that this may affect your ability to father a child. Talk to your doctor if<br />you have any questions or concerns about this.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with Pertensio should only be started and monitored by a doctor who has experience<br />in the treatment of PAH or systemic sclerosis. Always take this medicine exactly as your<br />doctor has told you. Check with your doctor or pharmacist if you are not sure.<br /><strong>Pertensio with food and drink</strong><br />Pertensio can be taken with or without food.<br /><strong>Recommended dose<br />Adult</strong><br />The treatment in adults is usually started for the first 4 weeks with 62.5 mg twice daily<br />(morning and evening), from then your doctor will usually advise you to take a 125 mg tablet<br />twice daily, depending on how you react to Pertensio.<br /><strong>Children and adolescents</strong><br />The dose recommendation in children is only for PAH. For children 1 year and older, treatment<br />with Pertensio is usually started with 2 mg per kg bodyweight twice daily (morning and<br />evening). Your doctor will advise you on your dosing.</p><p>If you have the impression that the effect of Pertensio is too strong or too weak, talk to your<br />doctor in order to find out whether your dose needs to be changed.<br /><strong>How to take Pertensio</strong><br />Tablets should be taken (morning and evening), swallowed with water. The tablets can be<br />taken with or without food.<br /><strong>If you take more Pertensio than you should</strong><br />If you take more tablets than you have been told to take, contact your doctor immediately.<br /><strong>If you forget to take Pertensio</strong><br />If you forget to take Pertensio, take a dose as soon as you remember, then continue to take your<br />tablets at the usual times. Do not take a double dose to make up for forgotten tablets.<br /><strong>If you stop taking Pertensio</strong><br />Suddenly stopping your treatment with Pertensio may lead to your symptoms getting worse.<br />Do not stop taking Pertensio unless your doctor tells you to. Your doctor may tell you to reduce<br />the dose over a few days before stopping completely.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />The most serious side effects with Pertensio are:<br />&bull; Abnormal liver function which may affect more than 1 in 10 people<br />&bull; Anaemia which may affect up to 1 in 10 people. Anaemia may occasionally require blood<br />transfusion<br />Your liver and blood values will be monitored during treatment with Pertensio (see section 2).<br />It is important that you have these tests as ordered by your doctor.<br />Signs that your liver may not be working properly include:<br />&bull; Nausea (urge to vomit),<br />&bull; Vomiting,<br />&bull; Fever (high temperature),<br />&bull; Pain in your stomach (abdomen),<br />&bull; Jaundice (yellowing of your skin or the whites of your eyes),<br />&bull; Dark-coloured urine,<br />&bull; Itching of your skin,<br />&bull; Lethargy or fatigue (unusual tiredness or exhaustion),<br />&bull; Flu-like syndrome (joint and muscle pain with fever).<br />If you notice any of these signs tell your doctor immediately.<br /><u><strong>Other side effects:</strong></u><br /><strong>Very common (may affect more than one in 10 people):</strong><br />&bull; Headache,<br />&bull; Oedema (swelling of the legs and ankles or other signs of fluid retention).<br /><strong>Common (may affect up to one in 10 people):</strong><br />&bull; Flushed appearance or redness of skin,<br />&bull; Hypersensitivity reactions (including skin inflammation, itching and rash),<br />&bull; Gastrooesophageal reflux disease (acid reflux),<br />&bull; Diarrhoea,<br />&bull; Syncope (fainting),<br />&bull; Palpitations (fast or irregular heart beats),<br />&bull; Low blood pressure,</p><p>&bull; Nasal congestion.<br /><strong>Uncommon (may affect up to one in 100 people):</strong><br />&bull; Thrombocytopenia (low number of blood platelets),<br />&bull; Neutropenia/leukopenia (low number of white blood cells),<br />&bull; Elevated liver function tests with hepatitis (inflammation of the liver) including possible<br />exacerbation of underlying hepatitis and/or jaundice (yellowing of the skin or the whites of<br />the eyes).<br /><strong>Rare (may affect up to one in 1000 people):</strong><br />&bull; Anaphylaxis (general allergic reaction), angioedema (swelling, most commonly around the<br />eyes, lips, tongue or throat),<br />&bull; Cirrhosis (scarring) of the liver, liver failure (serious disturbance of liver function),<br />&bull; Blurred vision have also been reported at an unknown frequency (frequency cannot be<br />estimated from the available data).<br /><strong>Side effects in children and adolescents</strong><br />The side effects that have been reported in children treated with Pertensio are the same as those<br />in adults.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton and on the blister<br />after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Do not store above 30&deg;C.<br />This medicinal product does not require any special storage conditions.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist<br />how to throw away any medicines you no longer use. These measures will help to protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&minus; Pertensio 125 mg film-coated tablets: </strong>The active substance is bosentan. Each tablet<br />contains 125 mg of bosentan.<br /><strong>&minus; Pertensio 62.5 mg film-coated tablets:</strong> The active substance is bosentan. Each tablet<br />contains 62.5 mg of bosentan.<br /><strong>The other ingredients:</strong><br />Starch 1500, Sodium Starch Glycollate, Povidone 30, Magnesium Stearate, Opadry II<br />85F230061 Orange &amp; Purified Water BP.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                − Pertensio 62.5mg film-coated tablets: A light orange to orange colored, round, biconvex,
film-coated tablet, engraved with “77” on one side and plain on the other side.
− Pertensio 125mg film-coated tablets: A light orange to orange colored, oblong, biconvex,
film-coated tablet, engraved with “78” on one side and plain on the other side.
Reel OPA/AL/PVC contains 56 tablets per unit carton.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SPIMACO</strong><br />AlQassim pharmaceutical plant<br />Saudi Pharmaceutical Industries &amp;<br />Medical Appliance Corporation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflets is approved in January 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>أقراص بيرتينسيو تحتوى على مادة بوسينتان, والتى تثبط من هرمون يسمى إندوثيلين- 1 الموجود طبيعيا بالجسم, والذى<br />يسبب تضيق بالأوعية الدموية. بذلك يسبب بيرتينسيو تمدد فى الأوعية الدموية وينتمى إلى مجموعة من الأدوية تسمى<br />&quot;مثبطات مستقبلات إندوثيلين&quot;.<br /><strong>يستخدم بيرتينسيو فى علاج الحالات الآتية:<br />&bull; ارتفاع ضغط الدم الشرياني الرئوي:</strong> وهو مرض ينتج من تضيق شديد في الأوعية الدموية في الرئتين مما يؤدي إلى<br />ارتفاع ضغط الدم في الأوعية الدموية (الشرايين الرئوية) التي تحمل الدم من القلب إلى الرئتين. هذا الضغط يقلل من<br />كمية الأكسجين التي يمكن أن توجد في الدم من الرئتين، مما يجعل النشاط البدني أكثر صعوبة. بيرتينسيو يوسع<br />الشرايين الرئوية، مما يجعل من الأسهل على القلب ضخ الدم من خلالها. وهذا يقلل من ضغط الدم ويخفف من<br />الأعراض.<br />من ارتفاع ضغط الدم الشريانى الرئوى لتحسين القدرة على ممارسة III يستخدم بيرتينسيو لعلاج المرضى المصابين بالفئة<br />تشمل الحد &quot;III&quot; الرياضة (القدرة على تنفيذ النشاط البدني) والأعراض. &quot;الفئة&quot; تعكس مدى حدة المرض: حيث أن الفئة<br />من ارتفاع ضغط الدم II بشكل ملحوظ للنشاط البدنى. قد تبين أيضا تًحسن بعض الحالات من المرضى المصابين بالفئة<br />تشمل الحد الطفيف للنشاط البدنى. حالات ارتفاع ضغط الدم الشريانى الرئوى والتى &quot;II&quot; الشريانى الرئوى. علما بأن الفئة<br />يستخدم فيها بيرتينسيو قد تكون:<br />&bull; أولية (بمعنى أنها غيرمعلومة السبب),<br />&bull; مسببة بواسطة تصلب الجلد (وتسمى أيضا التصلب الجهازي, وهو مرض يشتمل على نمو غير طبيعي للأنسجة الضامة<br />التي تدعم الجلد وغيرها من الأجهزة).</p><p>&bull; مسببة خلقيا (مع الولادة) لوجود عيوب فى القلب مع وجود مجزئات (ممرات غير طبيعية) مما يتسبب في تدفق غير<br />طبيعي من الدم عبر القلب والرئتين.<br />&bull; تقرحات (قروح على أصابع اليدين والقدمين) في المرضى البالغين الذين يعانون من حالة تسمى تصلب الجلد.<br />بيرتينسيو يقلل من عدد القرح الجديدة التي تظهر على أصابع اليدين والقدمين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تقم بتناول أقراص بيرتينسيو فى الحالات الآتية:</strong><br />&bull; إذا كنت تعانى من فرط التحسس تجاه مادة بوسينتان أو أى من المكونات الأخرى لهذا الدواء (والمذكورة فى الفقرة رقم<br />.(6<br />&bull; إذا كنت تعانى من مشاكل بالكبد (اسأل طبيبك المعالج),<br />&bull; إذا كنتِ حاملا أو قد تصبحين حاملا بسبب عدم استخدام وسيلة موثوق بها لمنع الحمل. فضلا قومى بقراءة المعلومات<br />المدرجة تحت فقرة &quot;موانع الحمل&quot; وفقرة &quot;أدوية أخرى وبيرتينسيو&quot;.<br />&bull; إذا كنت تخضع للعلاج بواسطة سيكلوسبورين (وهو دواء يستخدم بعد زراعة الأعضاء أو لعلاج الصدفية).<br />فى حالة انطباق أى من تلك الحالات المذكورة أعلاه عليك, أخبر طبيبك المعالج.<br /><strong>التحذيرات والاحتياطات<br />الاختبارات التالية قد يجريها لك طبيبك المعالج قبل البدء فى العلاج</strong><br />&bull; فحص الدم للتحقق من وظيفة الكبد,<br />&bull; فحص الدم للتحقق من فقر الدم (انخفاض الهيموجلوبين),<br />&bull; اختبار الحمل إذا كنتِ امرأة في سن الإنجاب.<br />تم العثور على بعض المرضى الذين يتناولون بيرتينسيو أن يكون لديهم خلل فى نتائج اختبارات وظائف الكبد وفقر الدم<br />(انخفاض الهيموجلوبين).<br /><strong>أثناء العلاج قد يلجأ طبيبك المعالج إلى إجراء الاختبارات التالية:</strong><br />أثناء العلاج بواسطة بيرتينسيو, سوف يقوم طبيبك المعالج بإجراء اختبارات للدم لفحص وظائف الكبد لديك ومستوى<br />الهيموجلوبين بالدم.<br /><strong>اختبارات الدم لفحص وظائف الكبد</strong><br />سيكون معدل تلك الاختبارات مرة واحدة شهريا طوال فترة العلاج بأقراص بيرتينسيو. بعد زيادة الجرعة سيتم إجراء اختبار<br />إضافى بعد أسبوعين.<br /><strong>اختبارات الدم لفحص الأنيميا</strong><br />سيكون معدل تلك الاختبارات مرة واحدة شهريا خلال الأربعة أشهر الأولى من العلاج, ثم بعد ذلك مرة واحدة كل ثلاثة<br />أشهر, حيث قد يصابوا المرضى المعالجون بواسطة بيرتينسيو بالأنيميا.<br />إذا كانت النتائج غير طبيعية, فإن طبيبك المعالج قد يقرر تخفيض الجرعة أو التوقف عن العلاج بواسطة بيرتينسيو وأداء<br />المزيد من الاختبارات للتحقق من السبب.<br /><strong>الأطفال والمراهقين</strong><br />لا ينصح باستخدام أقراص بيرتينسيو فى حالة الأطفال المصابين بالتصلب الجهازى و مرض القرحة الرقمى المستمر. فضلا انظر الفقرة رقم 3. كيفية تناول أقراص بيرتينسيو.<br /><strong>بيرتينسيو والأدوية الأخرى</strong><br />يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخر ا أًي أدوية أخرى, بما في ذلك الأدوية التي تم الحصول<br />عليها دون وصفة طبية. من المهم بصفة خاصة أن تخبر طبيبك إذا كنت تتناول أيا مما يلى:</p><p>دواء يستخدم بعد عمليات زرع الأعضاء وعلاج الصدفية), والذي يجب ألا يستخدم جنبا إًلى جنب ) A &bull; سيكلوسبورين<br />مع بيرتينسيو.<br />&bull; سايروليماس أو تاكروليماس, وهي الأدوية المستخدمة بعد زرع الأعضاء, كما لا ينصح&nbsp; باستخدامها جنبا&nbsp;إًلى جنب مع<br />بيرتينسيو.<br />&bull; جليبنكلاميد (دواء مرضالسكري), ريفامبيسين (دواء السل) أو فلوكونازول (دواء ضد الالتهابات الفطرية), نيفيرابين<br />(دواء فيروس نقصالمناعة البشرية) حيث لا ينصح &nbsp;باستخدام هذه الأدوية جنبا إًلى جنب مع بيرتينسيو.<br />&bull; الأدوية الأخرى لعلاج عدوى فيروس نقص المناعة البشرية، والتي قد تتطلب مراقبة خاصة إذا استخدمت جنبا إًلى<br />جنب مع بيرتينسيو.<br />&bull; وسائل منع الحمل الهرمونية, والتي قد تكون ليست فعالة كأسلوب وحيد لمنع الحمل عند تناول بيرتينسيو.<br /><strong>القيادة واستخدام الآلات</strong><br />بيرتينسيو لديه تأثير ضئيل أو منعدم على القدرة على القيادة واستخدام الآلات. ومع ذلك، يمكن أن يسبب بيرتينسيو انخفاضا<br />فى ضغط الدم مما قد يجعلك تشعر بالدوار، وقد يؤثر على رؤيتك ويؤثر على قدرتك على القيادة واستخدام الآلات. لذا، إذا<br />كنت تشعر بالدوار أو عدم وضوح الرؤية في حين تناول بيرتينسيو, تجنب قيادة السيارة أو تشغيل أي أدوات أو آلات.<br /><strong>للمرأة فى سن الإنجاب</strong><br />لا تقومى بتناول أقراص بيرتينسيو إذا كننتِ حاملا أو تخططين للحمل.<br /><strong>اختبارات الحمل</strong><br />بيرتينسيو قد يسبب ضرر ا لًلأطفال المتكونين قبل بدء العلاج أو أثناء العلاج والذين لم يولدوا بعد. إذا كنتِ امرأة يمكن أن<br />تصبح حاملا ,ً سوف يطلب منك طبيبك المعالج إجراء اختبار الحمل قبل البدء بتناول بيرتينسيو, وبانتظام أثناء فترة تناول<br />أقراصبيرتينسيو.<br /><strong>وسائل منع الحمل</strong><br />إذا كان من الممكن لكِ أن تصبحى حاملا ،ً يجب عليكِ استخدام وسيلة موثوق بها لتحديد النسل (منع الحمل) أثناء تناول<br />بيرتينسيو. سيقوم الطبيب أو أخصائي أمراض النساء&nbsp; بنصحك حول وسائل منع الحمل الموثوق بها أثناء تناول بيرتينسيو.<br />لأن بيرتينسيو قد يحد من فعالية وسائل منع الحمل الهرمونية (مثل، وسائل منع الحمل عن طريق الفم، أو الحقن، أو الزرع،<br />أو الجلد), وهذه الطريقة في حد ذاتها لا يمكن الاعتماد عليها.<br />لذلك، إذا كنتِ تستخدمين وسائل منع الحمل الهرمونية يجب عليكِ أيضا&nbsp;اًستخدام أسلوب الحاجز (على سبيل المثال, الواقي<br />الأنثوي, أو الغشاء, أو وسائل منع الحمل الإسفنجية, أو استخدام الواقي الذكري لشريك حياتك). ينصح بإجراء اختبارات<br />الحمل الشهرية أثناء تناول بيرتينسيو إذا كانت المريضة فى سن الإنجاب.<br />أخبرى طبيبك المعالج فور ا إًذا أصبحتِ حاملا أًو تخططين للحمل في المستقبل القريب أثناء تناول بيرتينسيو.<br /><strong>الرضاعة الطبيعية</strong><br />أخبرى طبيبك المعالج فى الحال إذا كنتِ ترضعين طفلك طبيعيا .ً ينصح بالتوقف فورا عن الرضاعة الطبيعية فى حال تناول<br />بيرتينسيو, حيث أنه من غير المعلوم ما إذا كان هذا الدواء يفرز مع لبن الثدى.<br /><strong>الخصوبة</strong><br />إذا كنت رجلا فًمن الممكن أن يقلل بيرتينسيو من عدد الحيوانات المنوية الخاصة بك. لذلك, لا يمكن استبعاد أن هذا قد يؤثر<br />على قدرتك على إنجاب طفل. تحدث مع طبيبك إذا كان لديك أي أسئلة أو استفسارات حول هذا الموضوع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب بداية العلاج بواسطة بيرتينسيو مع مراقبة العلاج من خلال طبيب ذى خبرة فى علاج ارتفاع ضغط الدم الشرياني<br />الرئوي أو التصلب الجهازى. قم دائما بتناول هذا الدواء تماما كما أخبرك طبيبك المعالج. تحقق من خلال الطبيب أو الصيدلى<br />إذا كنت غير متأكدا.ّ<br /><strong>بيرتينسيو مع الطعام والشراب</strong><br />يمكن تناول أقراص بيرتينسيو مع الطعام أو بدونه.<br /><strong>الجرعة الموصى بها<br />فى حالة البالغين</strong></p><p>غالبا ما يبدأ العلاج للبالغين خلال الأربعة أسابيع الأولى بجرعة 62.5 ملجم مرتين يوميا (صباحا ومساءً ), بعد ذلك عادة يقوم الطبيب بوصف جرعة 125 ملجم مرتين يوميا,ً اعتمادا على كيفية تأثير بيرتينسيو على حالتك.<br /><strong>الأطفال والمراهقين</strong><br />الجرعة الموصى بها للأطفال هى فقط لعلاج ارتفاع ضغط الدم الشرياني الرئوي. للأطفال فى سن سنة واحدة من العمر فما<br />أكثر, عادة ما يبدأ العلاج بجرعة 2 ملجم لكل كجم من وزن الطفل مرتين يوميا (صباحا ومساءً ). سيقوم الطبيب المعالج<br />بتحديد الجرعة المناسبة.<br />إذا كان لديك انطباعا سواء بفرط قوة أو فرط ضعف تأثير بيرتينسيو عليك, تواصل مع طبيبك المعالج للتحقق ما إذا كانت<br />جرعتك تحتاج إلى تغيير.<br /><strong>كيفية تناول بيرتينسيو</strong><br />يجب تناول الأقراص (صباحا ومساءً ) وبلعها مع الماء. يمكن تناول الأقراص مع أو بدون الطعام.<br /><strong>إذا قمت بتناول بيرتينسيو أكثر مما ينبغى</strong><br />إذا قمت بتناول بيرتينسيو أكثر مما وصف لك الطبيب, تواصل مع طبيبك المعالج فور ا.ً<br /><strong>فى حالة نسيان تناول أقراص بيرتينسيو</strong><br />إذا نسيت تناول الجرعة الخاصة بك من أقراص بيرتينسيو, قم بتناولها حالما تتذكر, ثم استمر فى تناول الجرعات التالية فى<br />أوقاتها المعتادة. لا تقم بمضاعفة الجرعة لتعويض الجرعة المنسية.<br /><strong>فى حالة التوقف عن تناول أقراص بيرتينسيو</strong><br />التوقف المفاجئ عن تناول أقراص بيرتينسيو قد يسبب تفاقم الأعراض لديك. لا تتوقف عن تناول أقراص بيرتينسيو ما لم<br />يخبرك طبيبك المعالج بذلك. قد يطلب منك طبيبك المعالج خفض الجرعة على مدار أيام قليلة قبل التوقف نهائيا عن تناول<br />بيرتينسيو.<br />إذا كانت لديك أى أسئلة إضافية بشأن استخدام هذا الدواء, اسأل طبيبك المعالج أو الصيدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية, قد يسبب هذا الدواء أعراضا جًانبية, وإن لم تكن تحدث لكل من يتناول هذا الدواء.<br />أكثر الأعراض الجانبية خطورة مع بيرتينسيو هى:<br />&bull; خلل فى وظائف الكبد والتى قد تصيب أكثر من 1 لكل 10 مستخدمين لهذا الدواء.<br />&bull; أنيميا والتى قد تصيب ما قد يصل إلى 1 لكل 10 مستخدمين لهذا الدواء. أحيانا قد تتطلب الأ ي نميا نقل دم.<br />فحوصات الكبد والدم لديك سيتم رصدها أثناء العلاج بواسطة بيرتينسيو (انظر الفقرة رقم 2). من الضرورى اتباع تلك<br />الفحوصات طبقا لتعليمات الطبيب.<br />العلامات التى تدل على قصور فى وظيفة الكبد تشمل ما يلى:<br />&bull; غثيان (حث على التقيؤ),<br />&bull; قيء,<br />&bull; حمى (ارتفاع درجة الحرارة)،<br />&bull; ألم في المعدة (البطن)،<br />&bull; اليرقان (اصفرار الجلد أو اصفرار بياض العينين)،<br />&bull; تلون البول بلون داكن،<br />&bull; حكة الجلد،<br />&bull; خمول أو تعب (إرهاق غير معتاد)،<br />&bull; متلازمة تشبه الأنفلونزا (آلام المفاصل والعضلات مع الحمى).</p><p>إذا لاحظت أي من هذه العلامات أخبر طبيبك فور ا.ً<br /><strong><u>أعراض جانبية أخرى:</u><br />شائعة جدا (والتى قد تصيب أكثر من 1 لكل 10 مستخدمين لهذا الدواء):</strong><br />&bull; صداع,<br />&bull; وذمة (تورم في الساقين والكاحلين أو غيرها من علامات احتباس السوائل).<br />شائعة (والتى قد تصيب ما يصل إلى 1 لكل 10 مستخدمين لهذا الدواء):<br />&bull; مظهر متورد أو احمرار في الجلد,<br />&bull; تفاعلات فرط الحساسية (بما في ذلك التهاب الجلد والحكة والطفح الجلدي) ,<br />&bull; مرض الارتجاع المريئى (ارتجاع الحامض) ,<br />&bull; إسهال,<br />&bull; غشيان (إغماء) ,<br />&bull; خفقان (تسارع أو خفقان ضربات القلب) ,<br />&bull; انخفاض ضغط دم,<br />&bull; احتقان الأنف.<br /><strong>غير شائعة (والتى قد تصيب ما يصل إلى 1 لكل 100 مستخدم لهذا الدواء):</strong><br />&bull; نقص الصفيحات (انخفاض عدد الصفائح الدموية),<br />&bull; نقص العدلات / الكريات البيضاء (انخفاض عدد خلايا الدم البيضاء),<br />&bull; ارتفاع نتائج اختبارات وظائف الكبد مع التهاب الكبد بما في ذلك تفاقم محتمل لالتهاب الكبد الأساسي و / أو اليرقان<br />(اصفرار الجلد أو اصفرار بياض العينين).<br /><strong>نادرة (والتى قد تصيب ما يصل إلى 1 لكل 1000 مستخدم لهذا الدواء):</strong><br />&bull; الحساسية المفرطة (رد الفعل التحسسي العام), وذمة وعائية (تورم, والأكثر شيوعا&nbsp;حًول العينين والشفتين واللسان أو<br />الحلق),<br />&bull; تليف (تندب) من الكبد, فشل الكبد (اضطراب خطير في وظائف الكبد),<br />&bull; كما تم الإبلاغ عن عدم وضوح الرؤية في معدل تكرار غير معروف (لا يمكن تقديره من خلال البيانات المتاحة).<br /><strong>الأعراض الجانبية لدى الأطفال والمراهقين</strong><br />الأعراض الجانبية التي تم الإبلاغ عنها في الأطفال الذين عولجوا بواسطة بيرتينسيو هي نفسها كما هو الحال في الكبار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيد ا عًن متناول ونظر الأطفال.<br />علما بأن تاريخ .&quot;EXP&quot; لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة وعلى الشريط بعد كلمة<br />الصلاحية يشير إلى آخر يوم من الشهر المذكور.<br />لا يحُفظ هذا الدواء فى درجة حرارة أعلى من 30 درجة مئوية.<br />لا يتطلب هذا الدواء أى شروط خاصة للتخزين.</p><p>لا يجب التخلص من الأدوية عبر مياه الصرف الصحى أو النفايات المنزلية. اسأل الصيدلى عن كيفية التخلص من الأدوية<br />التى لم تعد بحاجة إليها. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&minus; بيرتينسيو 125 ملجم أقراص مغلفة بطبقة رقيقة: </strong>المادة الفعالة هى بوسينتان. يحتوى كل قرص على 125 ملجم من<br />مادة بوسينتان.<br /><strong>&minus; بيرتينسيو 62.5 ملجم أقراص مغلفة بطبقة رقيقة: </strong>المادة الفعالة هى بوسينتان. يحتوى كل قرص على 62.5 ملجم من<br />مادة بوسينتان.<br />مكونات أخرى:<br />ومياه منقاة. II نشا 1500 , نشا جليكولات الصوديوم, بوفيدون 30 , ستيرات مغنيسيوم, أوبادرى برتقالى<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right"><strong>&minus; بيرتينسيو 62.5 ملجم أقراص مغلفة بطبقة رقيقة:</strong> أقراص لونها برتقالى إلى برتقالى فاتح, مستديرة, ثنائية التحدب,<br />مغطاة بطبقة رقيقة, محفور على أحد جانبيها رقم &quot; 77 &quot; وجلية السطح من الجانب الآخر.<br /><strong>&minus; بيرتينسيو 125 ملجم أقراص مغلفة بطبقة رقيقة:</strong> أقراص لونها برتقالى إلى برتقالى فاتح, مستطيلة, ثنائية التحدب,<br />مغطاة بطبقة رقيقة, محفور على أحد جانبيها رقم &quot; 78 &quot; وجلية السطح من الجانب الآخر.<br />تحتوى كل عبوة على 56 قرصا مغلفا بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>إنتاج الدوائية<br />مصنع الأدوية بالقصيم،<br />الشركة السعودية للصناعات الدوائية والمستلزمات الطبية،<br />المملكة العربية السعودية.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            هذه النشرة تمت الموافقة عليها بتاريخ : فبراير 2017 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pertensio 62.5 mg film-coated tablets.
Pertensio 125 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Pertensio 62.5 mg film-coated tablets: each film-coated tablet contains 62.5 mg bosentan.
• Pertensio 125 mg film-coated tablets: each film-coated tablet contains 125 mg bosentan.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
• Pertensio 62.5mg film-coated tablets: A light orange to orange colored, round, biconvex,
film-coated tablet, engraved with “77” on one side and plain on the other side.
• Pertensio 125mg film-coated tablets: A light orange to orange colored, oblong, biconvex,
film-coated tablet, engraved with “78” on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications<br />Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and<br />symptoms in patients with WHO functional class III. Efficacy has been shown in:<br />&bull; Primary (idiopathic and heritable) pulmonary arterial hypertension<br />&bull; Pulmonary arterial hypertension secondary to scleroderma without significant interstitial<br />pulmonary disease<br />&bull; Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts<br />and Eisenmenger&#39;s physiology<br />Some improvements have also been shown in patients with pulmonary arterial hypertension<br />WHO functional class II (see section 5.1).<br />Pertensio is also indicated to reduce the number of new digital ulcers in patients with systemic<br />sclerosis and ongoing digital ulcer disease (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Method of administration<br />Tablets are to be taken orally morning and evening, with or without food. The film-coated<br />tablets are to be swallowed with water.<br />Posology<br />For Pulmonary arterial hypertension:<br />Treatment should only be initiated and monitored by a physician experienced in the treatment<br />of pulmonary arterial hypertension.<br />Adults<br />In adult patients, Pertensio treatment should be initiated at a dose of 62.5 mg twice daily for 4<br />weeks and then increased to the maintenance dose of 125 mg twice daily. The same</p><p>recommendations apply to re-introduction of Pertensio after treatment interruption (see section<br />4.4).<br />Paediatric population<br />Paediatric pharmacokinetic data have shown that bosentan plasma concentrations in children<br />with PAH aged from 1 year to 15 years were on average lower than in adult patients and were<br />not increased by increasing the dose of Pertensio above 2 mg/kg body weight or by increasing<br />the dosing frequency from twice daily to three times daily (see section 5.2). Increasing the dose<br />or the dosing frequency will likely not result in additional clinical benefit.<br />Based on these pharmacokinetic results, when used in children with PAH 1 year and older, the<br />recommended starting and maintenance dose is 2 mg/kg morning and evening.<br />In neonates with persistent pulmonary hypertension of the newborn (PPHN), the benefit of<br />bosentan has not been shown in the standard-of-care treatment. No recommendation on a<br />posology can be made (see sections 5.1 and 5.2).<br />Management in case of clinical deterioration of PAH<br />In the case of clinical deterioration (e.g., decrease in 6-minute walk test distance by at least<br />10% compared with pre-treatment measurement) despite Pertensio treatment for at least 8<br />weeks (target dose for at least 4 weeks), alternative therapies should be considered. However,<br />some patients who show no response after 8 weeks of treatment with Pertensio may respond<br />favourably after an additional 4 to 8 weeks of treatment.<br />In the case of late clinical deterioration despite treatment with Pertensio (i.e., after several<br />months of treatment), the treatment should be re-assessed. Some patients not responding well<br />to 125 mg twice daily of Pertensio may slightly improve their exercise capacity when the dose<br />is increased to 250 mg twice daily. A careful benefit/risk assessment should be made, taking<br />into consideration that the liver toxicity is dose dependent (see sections 4.4 and 5.1).<br />Discontinuation of treatment<br />There is limited experience with abrupt discontinuation of Pertensio in patients with pulmonary<br />arterial hypertension. No evidence for acute rebound has been observed. However, to avoid the<br />possible occurrence of harmful clinical deterioration due to potential rebound effect, gradual<br />dose reduction (halving the dose for 3 to 7 days) should be considered. Intensified monitoring<br />is recommended during the discontinuation period.<br />If the decision to withdraw Pertensio is taken, it should be done gradually while an alternative<br />therapy is introduced.<br />Systemic sclerosis with ongoing digital ulcer disease<br />Treatment should only be initiated and monitored by a physician experienced in the treatment<br />of systemic sclerosis.<br />Adults<br />Pertensio treatment should be initiated at a dose of 62.5 mg twice daily for 4 weeks and then<br />increased to the maintenance dose of 125 mg twice daily. The same recommendations apply to<br />re-introduction of Pertensio after treatment interruption (see section 4.4).<br />Controlled clinical study experience in this indication is limited to 6 months (see section 5.1).<br />The patient&#39;s response to treatment and need for continued therapy should be re-evaluated on a<br />regular basis. A careful benefit/risk assessment should be made, taking into consideration the<br />liver toxicity of bosentan (see sections 4.4 and 4.8).<br />Paediatric population<br />There are no data on the safety and efficacy in patients under the age of 18 years.<br />Pharmacokinetic data are not available for Pertensio in young children with this disease.</p><p>Special populations<br />Hepatic impairment<br />Pertensio is contraindicated in patients with moderate to severe liver dysfunction (see sections<br />4.3, 4.4 and 5.2). No dose adjustment is needed in patients with mild hepatic impairment (i.e.,<br />Child-Pugh class A) (see section 5.2).<br />Renal impairment<br />No dose adjustment is required in patients with renal impairment. No dose adjustment is<br />required in patients undergoing dialysis (see section 5.2).<br />Elderly<br />No dose adjustment is required in patients over the age of 65 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• Moderate to severe hepatic impairment, i.e., Child-Pugh class B or C (see section 5.2)
• Baseline values of liver aminotransferases, i.e., aspartate aminotransferases (AST) and/or
alanine aminotransferases (ALT), greater than 3 times the upper limit of normal (see section
4.4)
• Concomitant use of cyclosporine A (see section 4.5)
• Pregnancy (see sections 4.4 and 4.6)
• Women of childbearing potential who are not using reliable methods of contraception (see
sections 4.4, 4.5 and 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The efficacy of Pertensio has not been established in patients with severe pulmonary arterial<br />hypertension. Transfer to a therapy that is recommended at the severe stage of the disease (e.g.,<br />epoprostenol) should be considered if the clinical condition deteriorates (see section 4.2).<br />The benefit/risk balance of bosentan has not been established in patients with WHO class I<br />functional status of pulmonary arterial hypertension.<br />Pertensio should only be initiated if the systemic systolic blood pressure is higher than 85<br />mmHg.<br />Pertensio has not been shown to have a beneficial effect on the healing of existing digital<br />ulcers.<br />Liver function<br />Elevations in liver aminotransferases, i.e., aspartate and alanine aminotransferases (AST and/or<br />ALT), associated with bosentan are dose dependent. Liver enzyme changes typically occur<br />within the first 26 weeks of treatment but may also occur late in treatment (see section 4.8).<br />These increases may be partly due to competitive inhibition of the elimination of bile salts<br />from hepatocytes but other mechanisms, which have not been clearly established, are probably<br />also involved in the occurrence of liver dysfunction. The accumulation of bosentan in<br />hepatocytes leading to cytolysis with potentially severe damage of the liver, or an<br />immunological mechanism, are not excluded. Liver dysfunction risk may also be increased<br />when medicinal products that are inhibitors of the bile salt export pump, e.g., rifampicin,<br />glibenclamide and cyclosporine A (see sections 4.3 and 4.5), are co-administered with<br />bosentan, but limited data are available.</p><p>Liver aminotransferase levels must be measured prior to initiation of treatment and subsequently<br />at monthly intervals for the duration of treatment with Pertensio. In addition, liver<br />aminotransferase levels must be measured 2 weeks after any dose increase.<br />Recommendations in case of ALT/AST elevations</p><table border="1" cellspacing="1" cellpadding="1" style="width:688px"><tbody><tr><td style="width:328px">ALT/AST levels</td><td style="width:358px">Treatment and monitoring recommendations</td></tr><tr><td style="width:328px">&gt; 3 and &le; 5 &times; ULN</td><td style="width:358px">The result should be confirmed by a second liver test; if<br />confirmed, a decision should be made on an individual basis to<br />continue Pertensio, possibly at a reduced dose, or to stop Pertensio<br />administration (see section 4.2). Monitoring of aminotransferase<br />levels should be continued at least every 2 weeks. If the<br />aminotransferase levels return to pre-treatment values continuing<br />or re-introducing Pertensio according to the conditions described<br />below should be considered.</td></tr><tr><td style="width:328px">&gt; 5 and &le; 8 &times; ULN</td><td style="width:358px">The result should be confirmed by a second liver test; if<br />confirmed, treatment should be stopped and aminotransferase<br />levels monitored at least every 2 weeks. If the aminotransferase<br />levels return to pre-treatment values re-introducing Pertensio<br />according to the conditions described below should be considered.</td></tr><tr><td style="width:328px">&gt; 8 &times; ULN</td><td style="width:358px">Treatment must be stopped and re-introduction of Pertensio is not to be considered.</td></tr><tr><td colspan="2" style="width:328px">In the case of associated clinical symptoms of liver injury, i.e., nausea, vomiting, fever, abdominal<br />pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia,<br />fever), treatment must be stopped and re-introduction of Pertensio is not to be considered.<br />Re-introduction of treatment<br />Re-introduction of treatment with Pertensio should only be considered if the potential benefits of<br />treatment with Pertensio outweigh the potential risks and when liver aminotransferase levels are<br />within pre-treatment values. The advice of a hepatologist is recommended. Re-introduction must<br />follow the guidelines detailed in section 4.2. Aminotransferase levels must then be checked within<br />3 days after re-introduction, then again after a further 2 weeks, and thereafter according to the<br />recommendations above.</td></tr></tbody></table><p>ULN = Upper Limit of Normal<br />Haemoglobin concentration<br />Treatment with bosentan has been associated with dose-related decreases in haemoglobin<br />concentration (see section 4.8). In placebo-controlled studies, bosentan-related decreases in<br />haemoglobin concentration were not progressive, and stabilised after the first 4&ndash;12 weeks of<br />treatment. It is recommended that haemoglobin concentrations be checked prior to initiation of<br />treatment, every month during the first 4 months, and quarterly thereafter. If a clinically<br />relevant decrease in haemoglobin concentration occurs, further evaluation and investigation<br />should be undertaken to determine the cause and need for specific treatment. In the postmarketing<br />period, cases of anaemia requiring red blood cell transfusion have been reported (see<br />section 4.8).</p><p>Women of childbearing potential<br />As Pertensio may render hormonal contraceptives ineffective, and taking into account the risk<br />that pulmonary hypertension deteriorates with pregnancy as well as the teratogenic effects<br />observed in animals:<br />&bull; Pertensio treatment must not be initiated in women of childbearing potential unless they<br />practise reliable contraception and the result of the pre-treatment pregnancy test is negative<br />&bull; Hormonal contraceptives cannot be the sole method of contraception during treatment with<br />Pertensio<br />&bull; Monthly pregnancy tests are recommended during treatment to allow early detection of<br />pregnancy<br />For further information see sections 4.5 and 4.6.<br />Pulmonary veno-occlusive disease<br />Cases of pulmonary oedema have been reported with vasodilators (mainly prostacyclins) when<br />used in patients with pulmonary veno-occlusive disease. Consequently, should signs of<br />pulmonary oedema occur when Pertensio is administered in patients with PAH, the possibility<br />of associated veno-occlusive disease should be considered. In the post-marketing period there<br />have been rare reports of pulmonary oedema in patients treated with Pertensio who had a<br />suspected diagnosis of pulmonary veno-occlusive disease.<br />Pulmonary arterial hypertension patients with concomitant left ventricular failure<br />No specific study has been performed in patients with pulmonary hypertension and<br />concomitant left ventricular dysfunction. However, 1,611 patients (804 bosentan- and 807<br />placebo-treated patients) with severe chronic heart failure (CHF) were treated for a mean<br />duration of 1.5 years in a placebo-controlled study (study AC-052-301/302 [ENABLE 1 &amp; 2]).<br />In this study there was an increased incidence of hospitalisation due to CHF during the first 4&ndash;<br />8 weeks of treatment with bosentan, which could have been the result of fluid retention. In this<br />study, fluid retention was manifested by early weight gain, decreased haemoglobin<br />concentration and increased incidence of leg oedema. At the end of this study, there was no<br />difference in overall hospitalisations for heart failure nor in mortality between bosentan- and<br />placebo-treated patients. Consequently, it is recommended that patients be monitored for signs<br />of fluid retention (e.g., weight gain), especially if they concomitantly suffer from severe<br />systolic dysfunction. Should this occur, starting treatment with diuretics is recommended, or<br />the dose of existing diuretics should be increased. Treatment with diuretics should be<br />considered in patients with evidence of fluid retention before the start of treatment with<br />Pertensio.<br />Pulmonary arterial hypertension associated with HIV infection<br />There is limited clinical study experience with the use of Pertensio in patients with PAH<br />associated with HIV infection, treated with antiretroviral medicinal products (see section 5.1).<br />An interaction study between bosentan and lopinavir+ritonavir in healthy subjects showed<br />increased plasma concentrations of bosentan, with the maximum level during the first 4 days of<br />treatment (see section 4.5). When treatment with Pertensio is initiated in patients who require<br />ritonavir-boosted protease inhibitors, the patient&#39;s tolerability of Pertensio should be closely<br />monitored with special attention, at the beginning of the initiation phase, to the risk of<br />hypotension and to liver function tests. An increased long-term risk of hepatic toxicity and<br />haematological adverse events cannot be excluded when bosentan is used in combination with<br />antiretroviral medicinal products. Due to the potential for interactions related to the inducing</p><p>effect of bosentan on CYP450 (see section 4.5), which could affect the efficacy of<br />antiretroviral therapy, these patients should also be monitored carefully regarding their HIV<br />infection.<br />Pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD)<br />Safety and tolerability of bosentan was investigated in an exploratory, uncontrolled 12-week<br />study in 11 patients with pulmonary hypertension secondary to severe COPD (stage III of<br />GOLD classification). An increase in minute ventilation and a decrease in oxygen saturation<br />were observed, and the most frequent adverse event was dyspnoea, which resolved with<br />discontinuation of bosentan.<br />Concomitant use with other medicinal products<br />Concomitant use of Pertensio and cyclosporine A is contraindicated (see sections 4.3 and 4.5).<br />Concomitant use of Pertensio with glibenclamide, fluconazole and rifampicin is not<br />recommended. For further details please refer to section 4.5.<br />Concomitant administration of both a CYP3A4 inhibitor and a CYP2C9 inhibitor with<br />Pertensio should be avoided (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bosentan is an inducer of the cytochrome P450 (CYP) isoenzymes CYP2C9 and CYP3A4. In<br />vitro data also suggest an induction of CYP2C19. Consequently, plasma concentrations of<br />substances metabolised by these isoenzymes will be decreased when Pertensio is coadministered.<br />The possibility of altered efficacy of medicinal products metabolised by these<br />isoenzymes should be considered. The dosage of these products may need to be adjusted after<br />initiation, dose change or discontinuation of concomitant Pertensio treatment.<br />Bosentan is metabolised by CYP2C9 and CYP3A4. Inhibition of these isoenzymes may<br />increase the plasma concentration of bosentan (see ketoconazole). The influence of CYP2C9<br />inhibitors on bosentan concentration has not been studied. The combination should be used<br />with caution.<br />Fluconazole and other inhibitors of both CYP2C9 and CYP3A4: Concomitant administration<br />with fluconazole, which inhibits mainly CYP2C9, but to some extent also CYP3A4, could lead<br />to large increases in plasma concentrations of bosentan. The combination is not recommended.<br />For the same reason, concomitant administration of both a potent CYP3A4 inhibitor (such as<br />ketoconazole, itraconazole or ritonavir) and a CYP2C9 inhibitor (such as voriconazole) with<br />Pertensio is not recommended.<br />Cyclosporine A: co-administration of Pertensio and cyclosporine A (a calcineurin inhibitor) is<br />contraindicated (see section 4.3). When co-administered, initial trough concentrations of<br />bosentan were approximately 30-fold higher than those measured after bosentan alone. At<br />steady state, bosentan plasma concentrations were 3- to 4-fold higher than with bosentan alone.<br />The mechanism of this interaction is most likely inhibition of transport protein-mediated<br />uptake of bosentan into hepatocytes by cyclosporine. The blood concentrations of cyclosporine<br />A (a CYP3A4 substrate) decreased by approximately 50%. This is most likely due to induction<br />of CYP3A4 by bosentan.<br />Tacrolimus, sirolimus: co-administration of tacrolimus or sirolimus and Pertensio has not been<br />studied in man but co-administration of tacrolimus or sirolimus and Pertensio may result in<br />increased plasma concentrations of bosentan in analogy to co-administration with cyclosporine<br />A. Concomitant Pertensio may reduce the plasma concentrations of tacrolimus and sirolimus.<br />Therefore, concomitant use of Pertensio and tacrolimus or sirolimus is not advisable. Patients</p><p>in need of the combination should be closely monitored for adverse events related to Pertensio<br />and for tacrolimus and sirolimus blood concentrations.<br />Glibenclamide: co-administration of bosentan 125 mg twice daily for 5 days decreased the<br />plasma concentrations of glibenclamide (a CYP3A4 substrate) by 40%, with potential<br />significant decrease of the hypoglycaemic effect. The plasma concentrations of bosentan were<br />also decreased by 29%. In addition, an increased incidence of elevated aminotransferases was<br />observed in patients receiving concomitant therapy. Both glibenclamide and bosentan inhibit<br />the bile salt export pump, which could explain the elevated aminotransferases. This<br />combination should not be used. No drug-drug interaction data are available with the other<br />sulfonylureas.<br />Rifampicin: co-administration in 9 healthy subjects for 7 days of bosentan 125 mg twice daily<br />with rifampicin, a potent inducer of CYP2C9 and CYP3A4, decreased the plasma<br />concentrations of bosentan by 58%, and this decrease could achieve almost 90% in an<br />individual case. As a result, a significantly reduced effect of bosentan is expected when it is coadministered<br />with rifampicin. Concomitant use of rifampicin and Pertensio is not<br />recommended. Data on other CYP3A4 inducers, e.g., carbamazepine, phenobarbital, phenytoin<br />and St. John&#39;s wort are lacking, but their concomitant administration is expected to lead to<br />reduced systemic exposure to bosentan. A clinically significant reduction of efficacy cannot be<br />excluded.<br />Lopinavir+ritonavir (and other ritonavir-boosted protease inhibitors): co-administration of<br />bosentan 125 mg twice daily and lopinavir+ritonavir 400+100 mg twice daily for 9.5 days in<br />healthy volunteers resulted in initial trough plasma concentrations of bosentan that were<br />approximately 48-fold higher than those measured after bosentan administered alone. On day<br />9, plasma concentrations of bosentan were approximately 5-fold higher than with bosentan<br />administered alone. Inhibition by ritonavir of transport protein-mediated uptake into<br />hepatocytes and of CYP3A4, thereby reducing the clearance of bosentan, most likely causes<br />this interaction. When administered concomitantly with lopinavir+ritonavir, or other ritonavirboosted<br />protease inhibitors, the patient&#39;s tolerability of Pertensio should be monitored.<br />After co-administration of bosentan for 9.5 days, the plasma exposures to lopinavir and<br />ritonavir decreased to a clinically non significant extent (by approximately 14% and 17%,<br />respectively). However, full induction by bosentan might not have been reached and a further<br />decrease of protease inhibitors cannot be excluded. Appropriate monitoring of the HIV therapy<br />is recommended. Similar effects would be expected with other ritonavir-boosted protease<br />inhibitors (see section 4.4).<br />Other antiretroviral agents: no specific recommendation can be made with regard to other<br />available antiretroviral agents due to the lack of data. Due to the marked hepatotoxicity of<br />nevirapine, which could add to bosentan liver toxicity, this combination is not recommended.<br />Hormonal contraceptives: co-administration of bosentan 125 mg twice daily for 7 days with a<br />single dose of oral contraceptive containing norethisterone 1 mg + ethinyl estradiol 35 mcg<br />decreased the AUC of norethisterone and ethinyl estradiol by 14% and 31%, respectively.<br />However, decreases in exposure were as much as 56% and 66%, respectively, in individual<br />subjects. Therefore, hormone-based contraceptives alone, regardless of the route of<br />administration (i.e., oral, injectable, transdermal or implantable forms), are not considered as<br />reliable methods of contraception (see sections 4.4 and 4.6).<br />Warfarin: co-administration of bosentan 500 mg twice daily for 6 days decreased the plasma<br />concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate)</p><p>by 29% and 38%, respectively. Clinical experience with concomitant administration of<br />bosentan with warfarin in patients with pulmonary arterial hypertension did not result in<br />clinically relevant changes in International Normalized Ratio (INR) or warfarin dose (baseline<br />versus end of the clinical studies). In addition, the frequency of changes in warfarin dose<br />during the studies due to changes in INR or due to adverse events was similar among bosentanand<br />placebo-treated patients. No dose adjustment is needed for warfarin and similar oral<br />anticoagulant agents when bosentan is initiated, but intensified monitoring of INR is<br />recommended, especially during bosentan initiation and the up-titration period.<br />Simvastatin: co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma<br />concentrations of simvastatin (a CYP3A4 substrate) and its active &beta;-hydroxy acid metabolite<br />by 34% and 46%, respectively. The plasma concentrations of bosentan were not affected by<br />concomitant simvastatin. Monitoring of cholesterol levels and subsequent dosage adjustment<br />should be considered.<br />Ketoconazole: co-administration for 6 days of bosentan 62.5 mg twice daily with ketoconazole,<br />a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan approximately 2-<br />fold. No dose adjustment of Pertensio is considered necessary. Although not demonstrated<br />through in vivo studies, similar increases in bosentan plasma concentrations are expected with<br />the other potent CYP3A4 inhibitors (such as itraconazole or ritonavir). However, when<br />combined with a CYP3A4 inhibitor, patients who are poor metabolisers of CYP2C9 are at risk<br />of increases in bosentan plasma concentrations that may be of higher magnitude, thus leading<br />to potential harmful adverse events.<br />Epoprostenol: limited data obtained from a study (AC-052-356 [BREATHE-3]) in which 10<br />paediatric patients received the combination of bosentan and epoprostenol indicate that after<br />both single- and multiple-dose administration, the Cmax and AUC values of bosentan were<br />similar in patients with or without continuous infusion of epoprostenol (see section 5.1).<br />Sildenafil: co-administration of bosentan 125 mg twice daily (steady state) with sildenafil 80<br />mg three times a day (at steady state) concomitantly administered during 6 days in healthy<br />volunteers resulted in a 63% decrease in the sildenafil AUC and a 50% increase in the bosentan<br />AUC. Caution is recommended in the case of co-administration.<br />Digoxin: co-administration for 7 days of bosentan 500 mg twice daily with digoxin decreased<br />the AUC, Cmax and Cmin of digoxin by 12%, 9% and 23%, respectively. The mechanism for this<br />interaction may be induction of P-glycoprotein. This interaction is unlikely to be of clinical<br />relevance.<br />Paediatric population<br />Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Pregnancy category: X<br />Studies in animals have shown reproductive toxicity (teratogenicity, embryotoxicity, see<br />section 5.3). There are no reliable data on the use of Pertensio in pregnant women. The<br />potential risk for humans is still unknown. Pertensio is contraindicated in pregnancy (see<br />section 4.3).<br />Women of childbearing potential<br />Before the initiation of Pertensio treatment in women of childbearing potential, the absence of<br />pregnancy should be checked, appropriate advice on reliable methods of contraception</p><p>provided, and reliable contraception initiated. Patients and prescribers must be aware that due<br />to potential pharmacokinetic interactions, Pertensio may render hormonal contraceptives<br />ineffective (see section 4.5). Therefore, women of childbearing potential must not use<br />hormonal contraceptives (including oral, injectable, transdermal or implantable forms) as the<br />sole method of contraception but must use an additional or an alternative reliable method of<br />contraception. If there is any doubt about what contraceptive advice should be given to the<br />individual patient, consultation with a gynaecologist is recommended. Because of possible<br />hormonal contraception failure during Pertensio treatment, and also bearing in mind the risk<br />that pulmonary hypertension severely deteriorates with pregnancy, monthly pregnancy tests<br />during treatment with Pertensio are recommended to allow early detection of pregnancy.<br />Breast-feeding<br />It is not known whether bosentan is excreted into human breast milk. Breast-feeding is not<br />recommended during treatment with Pertensio.<br />Fertility<br />Animal studies showed testicular effects (see section 5.3). In a study investigating the effects of<br />bosentan on testicular function in male PAH patients, 8 out of 24 patients showed a decreased<br />sperm concentration from baseline of at least 42% after 3 or 6 months of treatment with<br />bosentan. Based on these findings and preclinical data, it cannot be excluded that bosentan may<br />have a detrimental effect on spermatogenesis in men. In male children, a long-term impact on<br />fertility after treatment with bosentan cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific studies have been conducted to assess the direct effect of Pertensio on the ability to<br />drive and use machines. However, Pertensio may induce hypotension, with symptoms of<br />dizziness, blurred vision or syncope that could affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In 20 placebo-controlled studies, conducted in a variety of therapeutic indications, a total of<br />2,486 patients were treated with bosentan at daily doses ranging from 100 mg to 2000 mg and<br />1,838 patients were treated with placebo. The mean treatment duration was 45 weeks. Adverse<br />reactions were defined as events occurring in at least 1% of patients on bosentan and at a<br />frequency at least 0.5% more than on placebo. The most frequent adverse reactions are<br />headache (11.5%), oedema/fluid retention (13.2%), abnormal liver function test (10.9%) and<br />anaemia/haemoglobin decrease (9.9%).<br />Treatment with bosentan has been associated with dose-dependent elevations in liver<br />aminotransferases and decreases in haemoglobin concentration (see section 4.4, Special<br />warnings and precautions for use).<br />Adverse reactions observed in 20 placebo-controlled studies and post-marketing experience<br />with bosentan are ranked according to frequency using the following convention: very common<br />(&ge; 1/10); common (&ge;1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt;<br />1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).<br />Within each frequency grouping, adverse reactions are presented in order of decreasing<br />seriousness. No clinically relevant differences in adverse reactions were observed between the<br />overall dataset and the approved indications.</p><table border="1" cellspacing="1" cellpadding="1" style="width:708px"><tbody><tr><td style="width:209px">System organ class</td><td style="width:244px">Frequency</td><td style="width:253px">Adverse reaction</td></tr><tr><td style="width:209px">Blood and lymphatic system<br />disorders</td><td style="width:244px">Common</td><td style="width:253px">Anaemia, haemoglobin<br />decrease, (see section 4.4)</td></tr><tr><td style="width:209px">&nbsp;</td><td style="width:244px">Not known</td><td style="width:253px">Anaemia or haemoglobin<br />decreases requiring red<br />blood cell transfusion1</td></tr><tr><td style="width:209px">&nbsp;</td><td style="width:244px">Uncommon</td><td style="width:253px">Thrombocytopenia1</td></tr><tr><td style="width:209px">&nbsp;</td><td style="width:244px">Uncommon</td><td style="width:253px">Neutropenia, leukopenia1</td></tr><tr><td style="width:209px">Immune system disorders</td><td style="width:244px">Common</td><td style="width:253px">Hypersensitivity reactions<br />(including dermatitis,<br />pruritus and rash)2</td></tr><tr><td style="width:209px">&nbsp;</td><td style="width:244px">Rare</td><td style="width:253px">Anaphylaxis and/or<br />angioedema1</td></tr><tr><td style="width:209px">Nervous system disorders</td><td style="width:244px">Very common</td><td style="width:253px">Headache3,</td></tr><tr><td style="width:209px">&nbsp;</td><td style="width:244px">Common</td><td style="width:253px">Syncope1, 4</td></tr><tr><td style="width:209px">Eye disorders</td><td style="width:244px">Not known</td><td style="width:253px">Blurred vision1</td></tr><tr><td style="width:209px">Cardiac disorders</td><td style="width:244px">Common</td><td style="width:253px">Palpitations1, 4</td></tr><tr><td style="width:209px">Vascular disorders</td><td style="width:244px">Common</td><td style="width:253px">Flushing</td></tr><tr><td style="width:209px">&nbsp;</td><td style="width:244px">Common</td><td style="width:253px">Hypotension1, 4</td></tr><tr><td style="width:209px">Respiratory, thoracic and<br />mediastinal disorders</td><td style="width:244px">Common</td><td style="width:253px">Nasal congestion1</td></tr><tr><td style="width:209px">Gastrointestinal disorders</td><td style="width:244px">Common</td><td style="width:253px">Gastrooesophageal reflux<br />disease<br />Diarrhoea</td></tr><tr><td style="width:209px">Hepatobiliary disorders</td><td style="width:244px">Very common</td><td style="width:253px">Abnormal liver function<br />test , (see section 4.4)</td></tr><tr><td style="width:209px">&nbsp;</td><td style="width:244px">Uncommon</td><td style="width:253px">Aminotransferase<br />elevations associated with<br />hepatitis (including<br />possible exacerbation of<br />underlying hepatitis)<br />and/or jaundice1 (see<br />section 4.4)</td></tr><tr><td style="width:209px">&nbsp;</td><td style="width:244px">Rare</td><td style="width:253px">Liver cirrhosis, liver<br />failure1</td></tr><tr><td style="width:209px">Skin and subcutaneous disorders</td><td style="width:244px">Common</td><td style="width:253px">Erythema</td></tr><tr><td style="width:209px">General disorders and administration<br />site conditions</td><td style="width:244px">Very common</td><td style="width:253px">Oedema, fluid retention5</td></tr></tbody></table><p>1 Data derived from post-marketing experience, frequencies based on statistical modelling of<br />placebo-controlled clinical trial data.<br />2 Hypersensitivity reactions were reported in 9.9% of patients on bosentan and 9.1% of patients<br />on placebo.<br />3Headache was reported in 11.5% of patients on bosentan and 9.8% of patients on placebo.<br />4 These types of reactions can also be related to the underlying disease.<br />5Oedema or fluid retention was reported in 13.2% of patients on bosentan and 10.9% of<br />patients on placebo.<br />In the post-marketing period rare cases of unexplained hepatic cirrhosis were reported after<br />prolonged therapy with Pertensio in patients with multiple co-morbidities and therapies with<br />medicinal products. There have also been rare reports of liver failure. These cases reinforce the<br />importance of strict adherence to the monthly schedule for monitoring of liver function for the<br />duration of treatment with Pertensio (see section 4.4).<br />Paediatric population<br />Uncontrolled clinical studies in paediatric patients:<br />The safety profile in the first paediatric uncontrolled study performed with the film-coated<br />tablet (BREATHE-3: n = 19, median age 10 years [range 3&ndash;15 years], open-label bosentan 2<br />mg/kg twice daily; treatment duration 12 weeks) was similar to that observed in the pivotal<br />trials in adult patients with PAH. In BREATHE-3, the most frequent adverse reactions were<br />flushing (21%), headache, and abnormal liver function test (each 16%).<br />A pooled analysis of uncontrolled paediatric studies conducted in PAH with the bosentan 32<br />mg dispersible tablet formulation (FUTURE 1/2, FUTURE 3/Extension) included a total of<br />100 children treated with bosentan 2 mg/kg twice daily (n = 33), 2 mg/kg three times daily (n =<br />31), or 4 mg/kg twice daily (n = 36). At enrolment, six patients were between 3 months and 1<br />year old, 15 children were between 1 and less than 2 years old, and 79 were between 2 and 12<br />years old. The median treatment duration was 71.8 weeks (range 0.4&ndash;258 weeks).<br />The safety profile in this pooled analysis of uncontrolled paediatric studies was similar to that<br />observed in the pivotal trials in adult patients with PAH except for infections, which were more<br />frequently reported than in adults (69.0% vs 41.3%).This difference in infection frequency may<br />in part be due to the longer median treatment exposure in the paediatric set (median 71.8<br />weeks) compared to the adult set (median 17.4 weeks). The most frequent adverse events were<br />upper respiratory tract infections (25%), pulmonary (arterial) hypertension (20%),<br />nasopharyngitis (17%), pyrexia (15%), vomiting (13%), bronchitis (10%), abdominal pain<br />(10%), and diarrhoea (10%). There was no relevant difference in adverse event frequencies<br />between patients above and below the age of 2 years, however this is based on only 21 children<br />less than 2 years, including 6 patients between 3 months to 1 year of age. Adverse events of<br />liver abnormalities and anaemia/haemoglobin decrease occurred in 9% and 5% of patients,<br />respectively.<br />In a randomised placebo-controlled study, conducted in PPHN patients (FUTURE-4), a total of<br />13 neonates were treated with the bosentan dispersible tablet formulation at a dose of 2 mg/kg<br />twice daily (8 patients were on placebo). The median bosentan and placebo treatment duration<br />was, respectively, 4.5 days (range 0.5&ndash;10.0 days) and 4.0 days (range 2.5-6.5 days). The most<br />frequent adverse events in the bosentan- and the placebo-treated patients were, respectively,<br />anaemia or haemoglobin decrease (7 and 2 patients), generalised oedema (3 and 0 patients),<br />and vomiting (2 and 0 patients).</p><p>Laboratory abnormalities<br />Liver test abnormalities<br />In the clinical programme, dose-dependent elevations in liver aminotransferases generally<br />occurred within the first 26 weeks of treatment, usually developed gradually, and were mainly<br />asymptomatic. In the post-marketing period rare cases of liver cirrhosis and liver failure have<br />been reported.<br />The mechanism of this adverse effect is unclear. These elevations in aminotransferases may<br />reverse spontaneously while continuing treatment with the maintenance dose of Pertensio or<br />after dose reduction, but interruption or cessation may be necessary (see section 4.4).<br />In the 20 integrated placebo-controlled studies, elevations in liver aminotransferases &ge; 3 times<br />the upper limit of normal (ULN) were observed in 11.2% of the bosentan-treated patients as<br />compared to 2.4% of the placebo-treated patients. Elevations to &ge; 8 &times; ULN were seen in 3.6%<br />of the bosentan-treated patients and 0.4% of the placebo-treated patients. Elevations in<br />aminotransferases were associated with elevated bilirubin (&ge; 2 &times; ULN) without evidence of<br />biliary obstruction in 0.2% (5 patients) on bosentan and 0.3% (6 patients) on placebo.<br />In the pooled analysis of 100 PAH patients from uncontrolled paediatric studies FUTURE 1/2<br />and FUTURE 3/Extension, elevations in liver aminotransferases &ge; 3 &times; ULN were observed in<br />2% of patients.<br />In the FUTURE-4 study including 13 neonates with PPHN treated with bosentan 2 mg/kg<br />twice daily for less than 10 days (range 0.5&ndash;10.0 days) there were no cases of liver<br />aminotransferases &ge; 3 &times; ULN during treatment, but one case of hepatitis occurred 3 days after<br />the end of bosentan treatment.<br />Haemoglobin<br />In the adult placebo-controlled studies, a decrease in haemoglobin concentration to below 10<br />g/dL from baseline was reported in 8.0% of bosentan-treated patients and 3.9% of placebotreated<br />patients (see section 4.4).<br />In the pooled analysis of 100 PAH children from uncontrolled paediatric studies FUTURE 1/2<br />and FUTURE 3/Extension, a decrease in haemoglobin concentration from baseline to below 10<br />g/dL was reported in 10.0% of patients. There was no decrease to below 8 g/dL.<br />In the FUTURE-4 study, 6 out of 13 bosentan-treated neonates with PPHN experienced a<br />decrease in haemoglobin from within the reference range at baseline to below the lower limit<br />of normal during the treatment.</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>To report any side effect(s):<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bosentan has been administered as a single dose of up to 2400 mg to healthy subjects and up to<br />2000 mg/day for 2 months in patients with a disease other than pulmonary hypertension. The<br />most common adverse reaction was headache of mild to moderate intensity.<br />Massive overdose may result in pronounced hypotension requiring active cardiovascular<br />support. In the post-marketing period there was one reported overdose of 10,000 mg of<br />Pertensio taken by an adolescent male patient. He had symptoms of nausea, vomiting,<br />hypotension, dizziness, sweating and blurred vision. He recovered completely within 24 hours<br />with blood pressure support. Note: bosentan is not removed through dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antihypertensives, ATC code: C02KX01<br />Mechanism of action<br />Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both endothelin A<br />and B (ETA and ETB) receptors. Bosentan decreases both pulmonary and systemic vascular<br />resistance resulting in increased cardiac output without increasing heart rate.<br />The neurohormone endothelin-1 (ET-1) is one of the most potent vasoconstrictors known and<br />can also promote fibrosis, cell proliferation, cardiac hypertrophy and remodelling, and is proinflammatory.<br />These effects are mediated by endothelin binding to ETA and ETB receptors<br />located in the endothelium and vascular smooth muscle cells. ET-1 concentrations in tissues<br />and plasma are increased in several cardiovascular disorders and connective tissue diseases,<br />including pulmonary arterial hypertension, scleroderma, acute and chronic heart failure,<br />myocardial ischaemia, systemic hypertension and atherosclerosis, suggesting a pathogenic role<br />of ET-1 in these diseases. In pulmonary arterial hypertension and heart failure, in the absence<br />of endothelin receptor antagonism, elevated ET-1 concentrations are strongly correlated with<br />the severity and prognosis of these diseases.<br />Bosentan competes with the binding of ET-1 and other ET peptides to both ETA and<br />ETB receptors, with a slightly higher affinity for ETA receptors (Ki = 4.1&ndash;43 nanomolar) than<br />for ETB receptors (Ki = 38&ndash;730 nanomolar). Bosentan specifically antagonises ET receptors<br />and does not bind to other receptors.<br />Efficacy<br />Animal models<br />In animal models of pulmonary hypertension, chronic oral administration of bosentan reduced<br />pulmonary vascular resistance and reversed pulmonary vascular and right ventricular<br />hypertrophy. In an animal model of pulmonary fibrosis, bosentan reduced collagen deposition<br />in the lungs.<br />Efficacy in adult patients with pulmonary arterial hypertension<br />Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted<br />in 32 (study AC-052-351) and 213 (study AC-052-352 [BREATHE-1]) adult patients with<br />WHO functional class III&ndash;IV pulmonary arterial hypertension (primary pulmonary<br />hypertension or pulmonary hypertension secondary mainly to scleroderma). After 4 weeks of<br />bosentan 62.5 mg twice daily, the maintenance doses studied in these studies were 125 mg<br />twice daily in AC-052-351, and 125 mg twice daily and 250 mg twice daily in AC-052-352.</p><p>Bosentan was added to patients&#39; current therapy, which could include a combination of<br />anticoagulants, vasodilators (e.g., calcium channel blockers), diuretics, oxygen and digoxin,<br />but not epoprostenol. Control was placebo plus current therapy.<br />The primary endpoint for each study was change in 6-minute walk distance at 12 weeks for the<br />first study and 16 weeks for the second study. In both studies, treatment with bosentan resulted<br />in significant increases in exercise capacity. The placebo-corrected increases in walk distance<br />compared to baseline were 76 metres (p = 0.02; t-test) and 44 metres (p = 0.0002; Mann-<br />Whitney U test) at the primary endpoint of each study, respectively. The differences between<br />the two groups, 125 mg twice daily and 250 mg twice daily, were not statistically significant<br />but there was a trend towards improved exercise capacity in the group treated with 250 mg<br />twice daily.<br />The improvement in walk distance was apparent after 4 weeks of treatment, was clearly<br />evident after 8 weeks of treatment and was maintained for up to 28 weeks of double-blind<br />treatment in a subset of the patient population.<br />In a retrospective responder analysis based on change in walking distance, WHO functional<br />class and dyspnoea of the 95 patients randomised to bosentan 125 mg twice daily in the<br />placebo-controlled studies, it was found that at week 8, 66 patients had improved, 22 were<br />stable and 7 had deteriorated. Of the 22 patients stable at week 8, 6 improved at week 12/16<br />and 4 deteriorated compared with baseline. Of the 7 patients who deteriorated at week 8, 3<br />improved at week 12/16 and 4 deteriorated compared with baseline.<br />Invasive haemodynamic parameters were assessed in the first study only. Treatment with<br />bosentan led to a significant increase in cardiac index associated with a significant reduction in<br />pulmonary artery pressure, pulmonary vascular resistance and mean right atrial pressure.<br />A reduction in symptoms of pulmonary arterial hypertension was observed with bosentan<br />treatment. Dyspnoea measurement during walk tests showed an improvement in bosentantreated<br />patients. In the AC-052-352 study, 92% of the 213 patients were classified at baseline<br />as WHO functional class III and 8% as class IV. Treatment with bosentan led to a WHO<br />functional class improvement in 42.4% of patients (placebo 30.4%). The overall change in<br />WHO functional class during both studies was significantly better among bosentan-treated<br />patients as compared with placebo-treated patients. Treatment with bosentan was associated<br />with a significant reduction in the rate of clinical worsening compared with placebo at 28<br />weeks (10.7% vs 37.1%, respectively; p = 0.0015).<br />In a randomised, double-blind, multi-centre, placebo-controlled study (AC-052-364<br />[EARLY]), 185 PAH patients in WHO functional class II (mean baseline 6-minute walk<br />distance of 435 metres) received bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg<br />twice daily (n = 93), or placebo (n = 92) for 6 months. Enrolled patients were PAH-treatmentna&iuml;ve<br />(n = 156) or on a stable dose of sildenafil (n = 29). The co-primary endpoints were<br />percentage change from baseline in pulmonary vascular resistance (PVR) and change from<br />baseline in 6-minute walk distance to Month 6 versus placebo. The table below illustrates the<br />pre-specified protocol analyses.</p><table border="1" cellspacing="1" cellpadding="1" style="width:551px"><tbody><tr><td style="width:121px">&nbsp;</td><td rowspan="1" colspan="2" style="width:105px">PVR (dyn.sec/cm5)</td><td rowspan="1" colspan="2" style="width:136px">6-Minute Walk Distance (m)</td></tr><tr><td style="width:121px">&nbsp;</td><td style="width:105px">Placebo (n=88)</td><td style="width:102px">Bosentan (n=80)</td><td style="width:136px">Placebo (n=91)</td><td style="width:85px">Bosentan<br />(n=86)</td></tr><tr><td style="width:121px">Baseline (BL); mean (SD)</td><td style="width:105px">802 (365)</td><td style="width:102px">851 (535)</td><td style="width:136px">431 (92)</td><td style="width:85px">443 (83)</td></tr><tr><td style="width:121px">Change from BL; mean (SD)</td><td style="width:105px">128 (465)</td><td style="width:102px">-69 (475)</td><td style="width:136px">-8 (79)</td><td style="width:85px">11 (74)</td></tr><tr><td style="width:121px">Treatment effect</td><td rowspan="1" colspan="2" style="width:105px">-22.6%</td><td rowspan="1" colspan="2" style="width:136px">19</td></tr><tr><td style="width:121px">95% CL</td><td rowspan="1" colspan="2" style="width:105px">-34, -10</td><td rowspan="1" colspan="2" style="width:136px">-4, 42</td></tr><tr><td style="width:121px">P-value</td><td rowspan="1" colspan="2" style="width:105px">&lt; 0.0001</td><td rowspan="1" colspan="2" style="width:136px">0.0758</td></tr></tbody></table><p>PVR = pulmonary vascular resistance<br />Treatment with bosentan was associated with a reduction in the rate of clinical worsening,<br />defined as a composite of symptomatic progression, hospitalisation for PAH and death,<br />compared with placebo (proportional risk reduction 77%, 95% CI 20%&ndash;94%, p = 0.0114). The<br />treatment effect was driven by improvement in the component symptomatic progression. There<br />was one hospitalisation related to PAH worsening in the bosentan group and three<br />hospitalisations in the placebo group. Only one death occurred in each treatment group during<br />the 6-month double-blind study period, therefore no conclusion can be drawn on survival.<br />Long-term data were generated from all 173 patients who were treated with bosentan in the<br />controlled phase and/or were switched from placebo to bosentan in the open-label extension<br />phase of the EARLY study. The mean duration of exposure to bosentan treatment was 3.6 &plusmn;<br />1.8 years (up to 6.1 years), with 73% of patients treated for at least 3 years and 62% for at least<br />4 years. Patients could receive additional PAH treatment as required in the open-label<br />extension. The majority of patients were diagnosed with idiopathic or heritable pulmonary<br />arterial hypertension (61%). Overall, 78% of patients remained in WHO functional class II.<br />Kaplan-Meier estimates of survival were 90% and 85% at 3 and 4 years after the start of<br />treatment, respectively. At the same timepoints, 88% and 79% of patients remained free from<br />PAH worsening (defined as all-cause death, lung transplantation, atrial septostomy or start of<br />intravenous or subcutaneous prostanoid treatment). The relative contributions of previous<br />placebo treatment in the double-blind phase and of other medications started during the openlabel<br />extension period are unknown.<br />In a prospective, multi-centre, randomised, double-blind, placebo-controlled study (AC-052-<br />405 [BREATHE-5]), patients with pulmonary arterial hypertension WHO functional class III<br />and Eisenmenger physiology associated with congenital heart disease received bosentan 62.5<br />mg twice daily for 4 weeks, then 125 mg twice daily for a further 12 weeks (n = 37, of whom<br />31 had a predominantly right to left, bidirectional shunt). The primary objective was to show<br />that bosentan did not worsen hypoxaemia. After 16 weeks, the mean oxygen saturation was<br />increased in the bosentan group by 1.0% (95% CI &ndash;0.7%&ndash;2.8%) as compared to the placebo<br />group (n = 17 patients), showing that bosentan did not worsen hypoxaemia. The mean<br />pulmonary vascular resistance was significantly reduced in the bosentan group (with a<br />predominant effect observed in the subgroup of patients with bidirectional intracardiac shunt).<br />After 16 weeks, the mean placebo-corrected increase in 6-minute walk distance was 53 metres<br />(p = 0.0079), reflecting improvement in exercise capacity. Twenty-six patients continued to<br />receive bosentan in the 24-week open-label extension phase (AC-052-409) of the BREATHE-5</p><p>study (mean duration of treatment = 24.4 &plusmn; 2.0 weeks) and, in general, efficacy was<br />maintained.<br />An open-label, non-comparative study (AC-052-362[BREATHE-4]) was performed in 16<br />patients with WHO functional class III PAH associated with HIV infection. Patients were<br />treated with bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg twice daily for a<br />further 12 weeks. After 16 weeks&#39; treatment, there were significant improvements from<br />baseline in exercise capacity: the mean increase in 6-minute walk distance was 91.4 metres<br />from 332.6 metres on average at baseline (p &lt; 0.001). No formal conclusion can be drawn<br />regarding the effects of bosentan on antiretroviral drug efficacy (see also section 4.4).<br />There are no studies to demonstrate beneficial effects of Pertensio treatment on survival.<br />However, long-term vital status was recorded for all 235 patients who were treated with<br />bosentan in the two pivotal placebo-controlled studies (AC-052-351 and AC-052-352) and/or<br />their two uncontrolled, open-label extensions. The mean duration of exposure to bosentan was<br />1.9 years &plusmn; 0.7 years (min: 0.1 years; max: 3.3 years) and patients were observed for a mean of<br />2.0 &plusmn; 0.6 years. The majority of patients were diagnosed as primary pulmonary hypertension<br />(72%) and were in WHO functional class III (84%). In this total population, Kaplan-Meier<br />estimates of survival were 93% and 84% 1 and 2 years after the start of treatment with<br />bosentan, respectively. Survival estimates were lower in the subgroup of patients with PAH<br />secondary to systemic sclerosis. The estimates may have been influenced by the initiation of<br />epoprostenol treatment in 43/235 patients.<br />Studies performed in children with pulmonary arterial hypertension<br />BREATHE-3 (AC-052-356)<br />Bosentan film-coated tablets were evaluated in an open-label uncontrolled study in 19<br />paediatric patients with pulmonary arterial hypertension aged 3 to 15 years. This study was<br />primarily designed as a pharmacokinetic study (see section 5.2). Patients had primary<br />pulmonary hypertension (10 patients) or pulmonary arterial hypertension related to congenital<br />heart diseases (9 patients) and were in WHO functional class II (n = 15 patients, 79%) or class<br />III (n = 4 patients, 21%) at baseline. Patients were divided into three body-weight groups and<br />dosed with bosentan at approximately 2 mg/kg twice daily for 12 weeks. Half of the patients in<br />each group were already being treated with intravenous epoprostenol and the dose of<br />epoprostenol remained constant for the duration of the study.<br />Haemodynamics were measured in 17 patients. The mean increase from baseline in cardiac<br />index was 0.5 L/min/m2, the mean decrease in mean pulmonary arterial pressure was 8 mmHg,<br />and the mean decrease in PVR was 389 dyn&middot;sec&middot;cm-5. These haemodynamic improvements<br />from baseline were similar with or without co-administration of epoprostenol. Changes in<br />exercise test parameters at week 12 from baseline were highly variable and none were<br />significant.<br />FUTURE 1/2 (AC-052-365/AC-052-367)<br />FUTURE 1 was an open-label, uncontrolled study that was conducted with the dispersible<br />tablet formulation of bosentan administered at a maintenance dose of 4 mg/kg twice daily to 36<br />patients from 2 to 11 years of age. It was primarily designed as a pharmacokinetic study (see<br />section 5.2). At baseline, patients had idiopathic (31 patients [86%]) or familial (5 patients<br />[14%]) PAH, and were in WHO functional class II (n = 23 patients, 64%) or class III (n = 13<br />patients, 36%). In the FUTURE 1 study, the median exposure to study treatment was 13.1<br />weeks (range: 8.4 to 21.1). 33 of these patients were provided with continued treatment with<br />bosentan dispersible tablets at a dose of 4 mg/kg twice daily in the FUTURE 2 uncontrolled</p><p>extension phase for a median overall treatment duration of 2.3 years (range: 0.2 to 5.0 years).<br />At baseline in FUTURE 1, 9 patients were taking epoprostenol. 9 patients were newly initiated<br />on PAH-specific medication during the study. The Kaplan-Meier event-free estimate for<br />worsening of PAH (death, lung transplantation, or hospitalisation for PAH worsening) at 2<br />years was 78.9%. The Kaplan-Meier estimate of overall survival at 2 years was 91.2%.<br />FUTURE 3 (AC-052-373)<br />In this open-label randomised study with the bosentan 32 mg dispersible tablet formulation, 64<br />children with stable PAH from 3 months to 11 years of age were randomised to 24 weeks<br />bosentan treatment 2 mg/kg twice daily (n = 33) or 2 mg/kg three times daily (n = 31). 43<br />(67.2%) were &ge; 2 years to 11 years old, 15 (23.4%) were between 1 and 2 years old, and 6<br />(9.4%) were between 3 months and 1 year old. The study was primarily designed as a<br />pharmacokinetic study (see section 5.2) and efficacy endpoints were only exploratory. The<br />aetiology of PAH, according to Dana Point classification, included idiopathic PAH (46%),<br />heritable PAH (3%), associated PAH after corrective cardiac surgery (38%), and PAH-CHD<br />associated with systemic-to-pulmonary shunts, including Eisenmenger syndrome (13%).<br />Patients were in WHO functional class I (n = 19 patients, 29 %), class II (n = 27 patients, 42%)<br />or class III (n = 18 patients, 28%) at start of study treatment. At study entry, patients were<br />treated with PAH medications (most frequently PDE-5 inhibitor [sildenafil] alone [35.9%],<br />bosentan alone [10.9%], and a combination of bosentan, iloprost, and sildenafil in 10.9% of<br />patients) and continued their PAH treatment during the study.<br />At study start, less than half of the patients included (45.3% = 29/64) had bosentan treatment<br />alone not combined with other PAH-medication. 40.6% (26/64) remained on bosentan<br />monotherapy during the 24 weeks of study treatment without experiencing PAH worsening.<br />The analysis on the global population included (64 patients) showed that the majority had<br />remained at least stable (i.e., without deterioration) based on non-paediatric-specific WHO<br />functional class assessment (97% twice daily, 100% three times daily) and physicians&#39; global<br />clinical impression (94% twice daily, 93% three times daily) during the treatment period. The<br />Kaplan-Meier event-free estimate for worsening of PAH (death, lung transplantation, or<br />hospitalisation for PAH worsening) at 24 weeks was 96.9% and 96.7% in the twice daily and<br />three times daily groups, respectively.<br />There was no evidence of any clinical benefit with 2 mg/kg three times daily as compared to 2<br />mg/kg twice daily dosing.<br />Study performed in neonates with persistent pulmonary hypertension of the newborn (PPHN):<br />FUTURE 4 (AC-052-391)<br />This was a double-blind, placebo-controlled, randomised study in pre-term or term neonates<br />(gestational age 36&ndash;42 weeks) with PPHN. Patients with suboptimal response to inhaled nitric<br />oxide (iNO) despite at least 4 hours of continuous treatment were treated with bosentan<br />dispersible tablets at 2 mg/kg twice daily (N = 13) or placebo (N = 8) via nasogastric tube as<br />add-on therapy on top of iNO until complete weaning of iNO or until treatment failure (defined<br />as need for extra-corporeal membrane oxygenation [ECMO] or initiation of alternative<br />pulmonary vasodilator) and for a maximum of 14 days.<br />The median exposure to study treatment was 4.5 (range: 0.5&ndash;10.0) days in the bosentan group<br />and 4.0 (range: 2.5&ndash;6.5) days in the placebo group.<br />The results did not indicate an additional benefit of bosentan in this population:<br />&bull; The median time to complete weaning from iNO was 3.7 days (95% CLs 1.17, 6.95) on<br />bosentan and 2.9 days (95% CLs 1.26, 4.23) on placebo (p = 0.34).</p><p>&bull; The median time to complete weaning from mechanical ventilation was 10.8 days (95% CLs<br />3.21, 12.21 days) on bosentan and 8.6 days (95% CLs 3.71, 9.66 days) on placebo (p = 0.24).<br />&bull; One patient in the bosentan group had treatment failure (need for ECMO as per protocol<br />definition), which was declared based on increasing Oxigenation Index values within 8 h after<br />the first study drug dose. This patient recovered within the 60-day follow-up period.<br />Combination with epoprostenol<br />The combination of bosentan and epoprostenol has been investigated in two studies: AC-052-<br />355 (BREATHE-2) and AC-052-356 (BREATHE-3). AC-052-355 was a multi-centre,<br />randomised, double-blind, parallel-group study of bosentan versus placebo in 33 patients with<br />severe pulmonary arterial hypertension who were receiving concomitant epoprostenol therapy.<br />AC-052-356 was an open-label, uncontrolled study; 10 of the 19 paediatric patients were on<br />concomitant bosentan and epoprostenol therapy during the 12-week study. The safety profile of<br />the combination was not different from the one expected with each component and the<br />combination therapy was well tolerated in children and adults. The clinical benefit of the<br />combination has not been demonstrated.<br />Systemic sclerosis with digital ulcer disease<br />Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted<br />in 122 (study AC-052-401 [RAPIDS-1]) and 190 (study AC-052-331 [RAPIDS-2]) adult<br />patients with systemic sclerosis and digital ulcer disease (either ongoing digital ulcers or a<br />history of digital ulcers within the previous year). In study AC-052-331, patients had to have at<br />least one digital ulcer of recent onset, and across the two studies 85% of patients had ongoing<br />digital ulcer disease at baseline. After 4 weeks of bosentan 62.5 mg twice daily, the<br />maintenance dose studied in both these studies was 125 mg twice daily. The duration of<br />double-blind therapy was 16 weeks in study AC-052-401, and 24 weeks in study AC-052-331.<br />Background treatments for systemic sclerosis and digital ulcers were permitted if they<br />remained constant for at least 1 month prior to the start of treatment and during the doubleblind<br />study period.<br />The number of new digital ulcers from baseline to study endpoint was a primary endpoint in<br />both studies. Treatment with bosentan resulted in fewer new digital ulcers for the duration of<br />therapy, compared with placebo. In study AC-052-401, during 16 weeks of double-blind<br />therapy, patients in the bosentan group developed a mean of 1.4 new digital ulcers vs 2.7 new<br />digital ulcers in the placebo group (p = 0.0042). In study AC-052-331, during 24 weeks of<br />double-blind therapy, the corresponding figures were 1.9 vs 2.7 new digital ulcers, respectively<br />(p = 0.0351). In both studies, patients on bosentan were less likely to develop multiple new<br />digital ulcers during the study and took longer to develop each successive new digital ulcer<br />than did those on placebo. The effect of bosentan on reduction of the number of new digital<br />ulcers was more pronounced in patients with multiple digital ulcers.<br />No effect of bosentan on time to healing of digital ulcers was observed in either study.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of bosentan have mainly been documented in healthy subjects. Limited<br />data in patients show that the exposure to bosentan in adult pulmonary arterial hypertension<br />patients is approximately 2-fold greater than in healthy adult subjects.<br />In healthy subjects, bosentan displays dose- and time-dependent pharmacokinetics. Clearance<br />and volume of distribution decrease with increased intravenous doses and increase with time.</p><p>After oral administration, the systemic exposure is proportional to dose up to 500 mg. At<br />higher oral doses, Cmax and AUC increase less than proportionally to the dose.<br />Absorption<br />In healthy subjects, the absolute bioavailability of bosentan is approximately 50% and is not<br />affected by food. The maximum plasma concentrations are attained within 3&ndash;5 hours.<br />Distribution<br />Bosentan is highly bound (&gt; 98%) to plasma proteins, mainly albumin. Bosentan does not<br />penetrate into erythrocytes.<br />A volume of distribution (Vss) of about 18 litres was determined after an intravenous dose of<br />250 mg.<br />Biotransformation and elimination<br />After a single intravenous dose of 250 mg, the clearance was 8.2 L/h. The terminal elimination<br />half-life (t1/2) is 5.4 hours.<br />Upon multiple dosing, plasma concentrations of bosentan decrease gradually to 50%&ndash;65% of<br />those seen after single dose administration. This decrease is probably due to auto-induction of<br />metabolising liver enzymes. Steady-state conditions are reached within 3&ndash;5 days.<br />Bosentan is eliminated by biliary excretion following metabolism in the liver by the<br />cytochrome P450 isoenzymes, CYP2C9 and CYP3A4. Less than 3% of an administered oral<br />dose is recovered in urine.<br />Bosentan forms three metabolites and only one of these is pharmacologically active. This<br />metabolite is mainly excreted unchanged via the bile. In adult patients, the exposure to the<br />active metabolite is greater than in healthy subjects. In patients with evidence of the presence<br />of cholestasis, the exposure to the active metabolite may be increased.<br />Bosentan is an inducer of CYP2C9 and CYP3A4 and possibly also of CYP2C19 and the Pglycoprotein.<br />In vitro, bosentan inhibits the bile salt export pump in hepatocyte cultures.<br />In vitro data demonstrated that bosentan had no relevant inhibitory effect on the CYP<br />isoenzymes tested (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1, 3A4). Consequently, bosentan is<br />not expected to increase the plasma concentrations of medicinal products metabolised by these<br />isoenzymes.<br />Pharmacokinetics in special populations<br />Based on the investigated range of each variable, it is not expected that the pharmacokinetics of<br />bosentan will be influenced by gender, body weight, race, or age in the adult population to any<br />relevant extent.<br />Children<br />Pharmacokinetics were studied in paediatric patients in 4 clinical studies (BREATHE-3,<br />FUTURE 1, FUTURE-3 and FUTURE-4 see section 5.1). Due to limited data in children<br />below 2 years of age, pharmacokinetics remain not well characterised in this age category.<br />Study AC-052-356 [BREATHE-3]) evaluated the pharmacokinetics of single and multiple oral<br />doses of the film-coated tablet formulation of bosentan in 19 children aged from 3 to 15 years<br />with pulmonary arterial hypertension (PAH) who were dosed on the basis of body weight with<br />2 mg/kg twice daily. In this study, the exposure to bosentan decreased with time in a manner<br />consistent with the known auto-induction properties of bosentan. The mean AUC (CV%)<br />values of bosentan in paediatric patients treated with 31.25, 62.5 or 125 mg twice daily were<br />3,496 (49), 5,428 (79), and 6,124 (27) ng&middot;h/mL, respectively, and were lower than the value of<br />8,149 (47) ng&middot;h/mL observed in adult patients with PAH receiving 125 mg twice daily. At</p><p>steady state, the systemic exposures in paediatric patients weighing 10&ndash;20 kg, 20&ndash;40 kg and &gt;<br />40 kg were 43%, 67% and 75%, respectively, of the adult systemic exposure.<br />In study AC-052-365 [FUTURE 1] dispersible tablets were administered in 36 PAH children<br />aged from 2 to 11 years. No dose proportionality was observed as steady-state bosentan plasma<br />concentrations and AUCs were similar at oral doses of 2 and 4 mg/kg (AUC : 3,577 ng&middot;h/mL<br />and 3,371 ng&middot;h/mL for 2 mg/kg twice daily and 4 mg/kg twice daily, respectively). The<br />average exposure to bosentan in these paediatric patients was about half the exposure in adult<br />patients at the 125 mg twice daily maintenance dose but showed a large overlap with the<br />exposures in adults.<br />In study AC-052-373 [FUTURE 3], using dispersible tablets, the exposure to bosentan in the<br />patients treated with 2 mg/kg twice daily was comparable to that in the FUTURE 1 study. In<br />the overall population (n = 31), 2 mg/kg twice daily resulted in a daily exposure of 8,535<br />ng&middot;h/mL; AUC was 4,268 ng&middot;h/mL (CV: 61%). In patients between 3 months and 2 years, the<br />daily exposure was 7,879 ng&middot;h/mL; AUC was 3,939 ng&middot;h/mL (CV: 72%). In patients between<br />3 months and 1 year (n=2), AUC was 5,914 ng&middot;h/mL (CV: 85%) and in patients between 1<br />and 2 years (n=7), AUC was 3,507 ng&middot;h/mL (CV: 70%). In the patients above 2 years (n = 22)<br />the daily exposure was 8,820 ng&middot;h/mL; AUC was 4,410 ng&middot;h/mL (CV: 58%). Dosing<br />bosentan 2 mg/kg three times daily did not increase exposure, daily exposure was 7,275<br />ng&middot;h/mL (CV: 83%, n = 27).<br />Based on the findings in studies BREATHE-3, FUTURE 1, and FUTURE-3, it appears that the<br />exposure to bosentan reaches a plateau at lower doses in paediatric patients than in adults, and<br />that doses higher than 2 mg/kg twice daily (4 mg/kg twice daily or 2 mg/kg three times daily)<br />will not result in greater exposure to bosentan in paediatric patients.<br />In study AC-052-391 [FUTURE 4] conducted in neonates, bosentan concentrations increased<br />slowly and continuously over the first dosing interval, resulting in low exposure (AUC0-12 in<br />whole blood: 164 ng&middot;h/mL, n = 11). At steady-state, AUC was 6,165 ng&middot;h/mL (CV: 133%, n =<br />7), which is similar to the exposure observed in adult PAH patients receiving 125 mg twice<br />daily and taking into account a blood/plasma distribution ratio of 0.6.<br />The consequences of these findings regarding hepatotoxicity are unknown. Gender and<br />concomitant use of intravenous epoprostenol had no significant effect on the pharmacokinetics<br />of bosentan.<br />Hepatic impairment<br />In patients with mildly impaired liver function (Child-Pugh class A) no relevant changes in the<br />pharmacokinetics have been observed. The steady-state AUC of bosentan was 9% higher and<br />the AUC of the active metabolite, Ro 48-5033, was 33% higher in patients with mild hepatic<br />impairment than in healthy volunteers.<br />The impact of moderately impaired liver function (Child-Pugh class B) on the<br />pharmacokinetics of bosentan and its primary metabolite Ro 48-5033 was investigated in a<br />study including 5 patients with pulmonary hypertension associated with portal hypertension<br />and Child-Pugh class B hepatic impairment, and 3 patients with pulmonary arterial<br />hypertension from other causes and normal liver function. In the patients with Child-Pugh class<br />B liver impairment, the mean (95% CI) steady-state AUC of bosentan was 360 (212-613)<br />ng.h/mL, i.e., 4.7 times higher, and the mean (95% CI) AUC of the active metabolite Ro 48-<br />5033 was 106 (58.4-192) ng.h/mL, i.e., 12.4 times higher than in the patients with normal liver<br />function (bosentan: mean [95% CI] AUC: 76.1 [9.07-638] ng.h/mL; Ro 48-5033: mean [95%<br />CI] AUC 8.57 [1.28-57.2] ng.h/ml). Though the number of patients included was limited and</p><p>with high variability, these data indicate a marked increase in the exposure to bosentan and its<br />primary metabolite Ro 48-5033 in patients with moderate liver function impairment (Child-<br />Pugh class B).<br />The pharmacokinetics of bosentan have not been studied in patients with Child-Pugh class C<br />hepatic impairment. Pertensio is contra-indicated in patients with moderate to severe hepatic<br />impairment, i.e., Child-Pugh class B or C (see section 4.3).<br />Renal impairment<br />In patients with severe renal impairment (creatinine clearance 15&ndash;30 mL/min), plasma<br />concentrations of bosentan decreased by approximately 10%. Plasma concentrations of<br />bosentan metabolites increased about 2-fold in these patients as compared to subjects with<br />normal renal function. No dose adjustment is required in patients with renal impairment. There<br />is no specific clinical experience in patients undergoing dialysis. Based on physicochemical<br />properties and the high degree of protein binding, bosentan is not expected to be removed from<br />the circulation by dialysis to any significant extent (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A 2-year carcinogenicity study in mice showed an increased combined incidence of<br />hepatocellular adenomas and carcinomas in males, but not in females, at plasma concentrations<br />about 2 to 4 times the plasma concentrations achieved at the therapeutic dose in humans. In<br />rats, oral administration of bosentan for 2 years produced a small, significant increase in the<br />combined incidence of thyroid follicular cell adenomas and carcinomas in males, but not in<br />females, at plasma concentrations about 9 to 14 times the plasma concentrations achieved at<br />the therapeutic dose in humans. Bosentan was negative in tests for genotoxicity. There was<br />evidence of a mild thyroid hormonal imbalance induced by bosentan in rats. However, there<br />was no evidence of bosentan affecting thyroid function (thyroxine, TSH) in humans.<br />The effect of bosentan on mitochondrial function is unknown.<br />Bosentan has been shown to be teratogenic in rats at plasma levels higher than 1.5 times the<br />plasma concentrations achieved at the therapeutic dose in humans. Teratogenic effects,<br />including malformations of the head and face and of the major vessels, were dose dependent.<br />The similarities of the pattern of malformations observed with other ET receptor antagonists<br />and in ET knock-out mice indicate a class effect. Appropriate precautions must be taken for<br />women of childbearing potential (see sections 4.3, 4.4 and 4.6).<br />Development of testicular tubular atrophy and impaired fertility has been linked with chronic<br />administration of endothelin receptor antagonists in rodents.<br />In fertility studies in male and female rats, no effects on sperm count, motility and viability, or<br />on mating performance or fertility were observed at exposures that were 21 and 43 times the<br />expected therapeutic level in humans, respectively; nor was there any adverse effect on the<br />development of the pre-implantation embryo or on implantation.<br />Slightly increased incidence of testicular tubular atrophy was observed in rats given bosentan<br />orally at doses as low as 125 mg/kg/day (about 4 times the maximum recommended human<br />dose [MRHD] and the lowest doses tested) for two years but not at doses as high as 1500<br />mg/kg/day (about 50 times the MRHD) for 6 months. In a juvenile rat toxicity study, where<br />rats were treated from Day 4 post partum up to adulthood, decreased absolute weights of testes<br />and epididymides, and reduced number of sperm in epididymides were observed after weaning.<br />The NOAEL was 21 times (at Day 21 post partum) and 2.3 times (Day 69 post partum) the<br />human therapeutic exposure, respectively.</p><p>However, no effects on general development, growth, sensory, cognitive function and<br />reproductive performance were detected at 7 (males) and 19 (females) times the human<br />therapeutic exposure at Day 21 post partum. At adult age (Day 69 post partum) no effects of<br />bosentan were detected at 1.3 (males) and 2.6 (females) times the therapeutic exposure in<br />children with PAH.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>DRY MIXING<br />Starch 1500<br />Sodium Starch Glycollate<br />GRANULATING SOLUTION<br />Povidone 30<br />Purified Water BP<br />EXTRAGRANULAR MATERIAL<br />Starch 1500<br />Magnesium Stearate<br />FILM-COATING<br />Opadry II 85F230061 Orange<br />Purified Water BP</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reel OPA/AL/PVC.<br />56 tablets per unit carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>